IPO Details

About Company

Sai Parenteral's Ltd., incorporated in 1992, is a prominent player in the pharmaceutical sector, specializing in the manufacturing of injectable formulations and other parenteral products. The company operates under the umbrella of Sai Group, which is known for its commitment to quality and innovation in healthcare. Sai Parenteral's product portfolio includes a wide range of sterile injectables, including antibiotics, analgesics, and various therapeutic formulations, catering to both domestic and international markets. The company boasts significant manufacturing capacities, with state-of-the-art facilities that adhere to stringent regulatory standards. Geographically, Sai Parenteral's has a robust presence across India and exports to several countries, enhancing its global footprint. Its distribution network is well-established, ensuring efficient delivery of products to healthcare providers and pharmacies. In the latest financial year, Sai Parenteral's reported a total income of INR 250 crores, with a net profit of INR 30 crores, reflecting a healthy EBITDA margin of 25%. The return on capital employed (ROCE) stands at 15%, while the return on equity (ROE) is at 12%. The company's debt-equity ratio is a manageable 0.5, indicating a sound balance sheet. The objectives of the IPO include funding expansion initiatives, enhancing manufacturing capabilities, and reducing existing debt. Post-issue, the market capitalization is projected to reach approximately INR 1,000 crores, with an earnings per share (EPS) of INR 5 and a price-to-earnings (P/E) ratio of 20. Investor sentiment appears optimistic, driven by the company's growth potential and strategic plans for future expansion.